Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities

Published:2019-01 Issue: Volume:193 Page:20-30
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Yoda Satoshi,Dagogo-Jack Ibiayi,Hata Aaron N.

Funder

Be a Piece of the Solution

Evan Spirito Foundation

Targeting a Cure for Lung Cancer Research Fund

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference163 articles.

1. An acquired NRAS Q61K mutation in BRAF V600E-mutant lung adenocarcinoma resistant to dabrafenib plus trametinib;Abravanel;Journal of Thoracic Oncology,2018

2. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial;Ahn;Journal of Thoracic Oncology,2016

3. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas;Arcila;Clinical Cancer Research,2012

4. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations;Asahina;British Journal of Cancer,2006

5. Acquired METD1228V mutation and resistance to MET inhibition in lung cancer;Bahcall;Cancer Discovery,2016

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular and functional characterization of reversible‐sunitinib‐tolerance state in human renal cell carcinoma;Journal of Cellular and Molecular Medicine;2024-05

2. Tumor-associated macrophages in non-small-cell lung cancer: From treatment resistance mechanisms to therapeutic targets;Critical Reviews in Oncology/Hematology;2024-04

3. Comprehensive Analysis for Predicting Prognoses and Immune Responses of m6A-Related lncRNAs in Women with Lung Adenocarcinoma;Biochemical Genetics;2023-11-24

4. Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells;Cell Death & Disease;2023-11-08

5. Identification of bioactive compounds from Vaccinium vitis-idaea L. (Lingonberry) as inhibitors for treating KRAS-associated cancer: a computational approach;In Silico Pharmacology;2023-10-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3